- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05392699
ABOD2011 en pacientes con tumores sólidos avanzados que progresaron después de la terapia sistémica estándar
Un estudio abierto ciego de escalada de dosis para evaluar la seguridad, la tolerabilidad y la eficacia preliminar de ABOD2011 en pacientes con tumores sólidos avanzados que progresaron después de la terapia sistémica estándar
Based on the activation and regulation of immune system by cytokines, mRNA encoding cytokines has become one of the important directions of mRNA tumor drug development. This product (ABOD2011) is a new generation mRNA product for intratumoral injection.
The primary objective of this study is to assess the safety and tolerability, of ABOD2011 in patients with advanced solid tumors that progressed after standard systemic therapy.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Beijing, Porcelana
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- 18 years and older.
- Understand and voluntarily sign the informed consent form (ICF).
- Histopathologically confirmed recurrent or metastatic solid tumors.
- Failure of prior systemic standard of care, or intolerance to severe toxicity, or lack of standard of care.
- Presence of at least one measurable lesion as assessed by RECIST Version 1.1.
- At least one superficial or deep lesion for intratumoral administration and biopsy.
- Sufficient organ functions.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.
- Weight > 30 kg.
- Expected survival longer than 12 weeks.
- Evidence of menopause in female patients, or for women of childbearing potential: negative for urine or blood pregnancy.
Exclusion Criteria:
- Any systemic anti-tumor therapy, within 28 days prior to the first dose.
- Radiotherapy within 14 days prior to first dose.
- Use of immunosuppressants.
- Major surgery within 28 days.
- Inadequately controlled diseases.
- Active autoimmune and inflammatory diseases.
- Clinically symptomatic central nervous system tumors or metastases.
- Toxicity of prior anti-tumor therapy is still NCI-CTCAE ≥ 2.
- Other malignancies within the previous 5 years with the exception of cured basal cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the breast, and carcinoma in situ of the cervix.
- Active infections.
- Other conditions that may increase the risk associated with the study drug, or affect the study compliance, etc., which, in the opinion of the investigator, are not suitable for participation in the study.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Human single chain IL-12 mRNA-single dose
Human single chain IL-12 mRNA-single dose |
human single chain IL-12 mRNA administered as specified in the treatment arm with injection once only |
|
Experimental: Human single chain IL-12 mRNA-multiple dose
Human single chain IL-12 mRNA-multiple dose |
human single chain IL-12 mRNA administered as specified in the treatment arm with injection once per week for 3 weeks |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of Participants Experiencing dose-limiting toxicities (DLTs)
Periodo de tiempo: From first dose to Day 28
|
Number of Participants Experiencing dose-limiting toxicities (DLTs) |
From first dose to Day 28
|
|
Number of Participants Experiencing Adverse Events (AEs)
Periodo de tiempo: From signed ICF until the date of last visit or start new antitumor therapy, whichever comes first, assessed up to 36 months
|
Number of Participants Experiencing Adverse Events (AEs) |
From signed ICF until the date of last visit or start new antitumor therapy, whichever comes first, assessed up to 36 months
|
|
Number of Participants Experiencing Severe Adverse Events (SAEs)
Periodo de tiempo: From signed ICF until the date of last visit or start new antitumor therapy, whichever came first, assessed up to 24 months
|
Number of Participants Experiencing Severe Adverse Events (SAEs) |
From signed ICF until the date of last visit or start new antitumor therapy, whichever came first, assessed up to 24 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Overall Response Rate (ORR)
Periodo de tiempo: Up to 36 months
|
Overall Response Rate (ORR) |
Up to 36 months
|
|
Disease Control Rate(DCR)
Periodo de tiempo: Up to 36 months
|
Disease Control Rate(DCR) |
Up to 36 months
|
|
Duration of Response (DOR)
Periodo de tiempo: Up to 36 months
|
Duration of Response (DOR) |
Up to 36 months
|
|
Progression-Free Survival (PFS)
Periodo de tiempo: Up to 36 months
|
Progression-Free Survival (PFS) |
Up to 36 months
|
|
Overall Survival
Periodo de tiempo: Up to 36 months
|
Overall Survival |
Up to 36 months
|
|
Maximum observed concentration (Cmax) of ABOD2011
Periodo de tiempo: From first dose of ABOD2011 through to 28 days after last dose of investigational product
|
Maximum observed concentration (Cmax) of ABOD2011 |
From first dose of ABOD2011 through to 28 days after last dose of investigational product
|
|
Area under the concentration-time curve (AUC) of ABOD2011
Periodo de tiempo: From first dose of ABOD2011 through to 28 days after last dose of investigational product
|
Area under the concentration-time curve (AUC) of ABOD2011 |
From first dose of ABOD2011 through to 28 days after last dose of investigational product
|
|
Maximum observed concentration (Cmax) of IL-12
Periodo de tiempo: From first dose of ABOD2011 through to 28 days after last dose of investigational product
|
Maximum observed concentration (Cmax) of IL-12 |
From first dose of ABOD2011 through to 28 days after last dose of investigational product
|
|
Area under the concentration-time curve (AUC) of IL-12
Periodo de tiempo: From first dose of ABOD2011 through to 28 days after last dose of investigational product.
|
Area under the concentration-time curve (AUC) of IL-12 |
From first dose of ABOD2011 through to 28 days after last dose of investigational product.
|
|
Plasma concentration of IFN gamma
Periodo de tiempo: From first dose of ABOD2011 through to 28 days after last dose of investigational product.
|
Plasma concentration of IFN gamma |
From first dose of ABOD2011 through to 28 days after last dose of investigational product.
|
Colaboradores e Investigadores
Investigadores
- Investigador principal: Ning Li, Doctor, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Otros números de identificación del estudio
- ABOD2011-001
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .